Tripla negatív emlőrák: vizsgálatok itt: Németország

In Németország 27 Also abroad 425

27 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.

3. fázisTaking people
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Where
Berlin, Düsseldorf, Erlangen, Essen, Leipzig, Saarbrücken
Életkor
18 év and over
People
1000 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06841354 · EU 2024-516834-36-00
3. fázisTaking people
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Where
Berlin, Duesseldorf, Erlangen, Hamburg, Koblenz, Muenster, Munich, Paderborn, Saarbruecken
Életkor
18 év and over
People
2400 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06966700 · EU 2024-520190-12-00
2. fázisNot yet taking people in Németország
An international study evaluating diagnostic and theranostic agents in patients with solid tumors and brain metastases.
Where
Munich
Életkor
18 év and over
People
20
Run by
Medica Scientia Innovation Research S.L.
See details and how to join2025-523824-39-01 · EU 2025-523824-39-01
1. fázisTaking people
START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
Where
Berlin, Frankfurt am Main, Goettingen, Heidelberg, Tübingen
Életkor
18 év and over
People
15 worldwide
Run by
Valo Therapeutics Oy
See details and how to joinNCT05492682 · EU 2024-517580-23-00
1/2. fázisTaking people
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
Where
Erlangen, Essen
Életkor
18 év and over
People
1132 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT03424005 · EU 2023-503629-20-00
3. fázisTaking people
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Where
Berlin, Chemnitz, Duesseldorf, Erlangen, Essen, Freiburg Im Breisgau, Georgsmarienhuette, Hamburg, Hanover, Ludwigsburg, Luebeck, Magdeburg, Mainz, Moenchengladbach, Munich, Potsdam, Saarbruecken, Trier, Troisdorf, Tuebingen, Westerstede, Witten
Életkor
18 év and over
People
1530 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06393374 · EU 2023-504962-52-00
3. fázisTaking people
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Where
Augsburg, Berlin, Bielefeld, Bottrop, Braunschweig, Bremen, Cologne, Dortmund, Dresden, Duesseldorf, Erlangen, Essen, Frankfurt am Main, Frankfurt Am Main, Freiburg im Breisgau, Gelsenkirchen, Georgsmarienhuette, Gera, Hamburg, Jena, Karlsruhe, Kassel, Kiel, Koblenz, Krefeld, Langen (Hessen), Leipzig, Mannheim, Muehlhausen/thueringen, Muenster, Munich, Offenbach Am Main, Oldenburg, Paderborn, Potsdam, Ravensburg, Rostock, Schwerin, Stade, Stuttgart, Tuebingen, Ulm, Wiesbaden, Witten, Worms, Wuppertal
Életkor
18 év and over
People
1514 worldwide
Run by
Gilead Sciences
See details and how to joinNCT05633654 · EU 2024-512279-10-00
3. fázisTaking people
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Where
Augsburg, Berlin, Braunschweig, Bremen, Dresden, Essen, Frankfurt Am Main, Freiburg Im Breisgau, Georgsmarienhuette, Gera, Hamburg, Koblenz, Mainz, Mannheim, Munich, Nuremberg, Ravensburg, Rostock, Worms
Életkor
18 év and over
People
558 worldwide
Run by
BioNTech SE
See details and how to joinNCT07173751 · EU 2025-521884-12-00
No phaseTaking people
Feasibility of a Lifestyle Intervention for Women With Triple-negative Breast Cancer Under Neoadjuvant Immunotherapy
Where
Essen
Életkor
18 év to 75 év
People
60
Run by
Kliniken Essen-Mitte
See details and how to joinNCT07311083
1. fázisNot yet taking people in Németország
A phase I study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with solid tumors
Where
Cologne, Essen
Életkor
18 év and over
People
64 worldwide
Run by
Novartis Pharma AG
See details and how to join2024-518348-19-00 · EU 2024-518348-19-00
1. fázisTaking people
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
Where
Essen
Életkor
18 év and over
People
180 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07261631
1/2. fázisTaking people
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Where
Augsburg, Essen, Frankfurt am Main, Hamburg, Heidelberg
Életkor
12 év and over
People
300 worldwide
Run by
PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750
3. fázisTaking people
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Where
Düsseldorf, Essen, Georgsmarienhütte, Hamburg, Hanover, Heidelberg, Heilbronn, Leipzig
Életkor
18 év and over
People
625 worldwide
Run by
AstraZeneca
See details and how to joinNCT06103864
1. fázisTaking people
A phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients with solid tumors
Where
Essen
Életkor
18 év and over
People
62 worldwide
Run by
Novartis Pharma AG
See details and how to join2025-521702-18-00 · EU 2025-521702-18-00
1/2. fázisTaking people
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Where
Dresden, Essen, Frankfurt, Ulm, Würzburg
Életkor
18 év and over
People
1109 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT04895709
2/3. fázisTaking people
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Where
Augsburg, Berlin, Bonn, Dresden, Essen, Esslingen am Neckar, Frankfurt Am Main, Hanover, Heidelberg, Langen (Hessen), Luebeck, Munich, Ulm
Életkor
18 év and over
People
600 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06926868 · EU 2024-519871-24-00
3. fázisNot yet taking people in Németország
NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer
Where
Aachen, Augsburg, Bad Nauheim, Bonn, Cologne, Cottbus, Dortmund, Eschweiler, Essen, Guetersloh, Hamburg, Hamm, Heilbronn, Hildesheim, Kassel, Moenchengladbach, Muenster, Munich, Regensburg, Rodewisch, Schwerte, Troisdorf, Weinheim, Witten, Wuerzburg
Életkor
18 év and over
People
765 worldwide
Run by
Women's Cancer Study Group GmbH
See details and how to joinNCT07178730 · EU 2024-516734-35-00
3. fázisTaking people
NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)
Where
Ahlen, Augsburg, Baden-Baden, Berlin, Bielefeld, Boeblingen, Bremen, Bremerhaven, Chemnitz, Cologne, Dortmund, Duesseldorf, Eschweiler, Essen, Frankfurt am Main, Freiburg, Freiburg Im Breisgau, Gelsenkirchen, Georgsmarienhuette, Gröbenzell, Hamburg, Hamm, Heilbronn, Herne, Hildesheim, Kassel, Leipzig, Leverkusen, Moenchengladbach, Muenster, Munich, Münster, Potsdam, Rastatt, Saarbruecken, Schwelm, Schwerte, Sindelfingen, Sinsheim, Stendal, Trier, Troisdorf, Tuebingen, Ulm, Weinheim, Witten, Wuppertal
Életkor
18 év and over
People
348
Run by
Women's Cancer Study Group GmbH
See details and how to joinNCT06081244 · EU 2023-508787-29-00
1. fázisTaking people
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Where
Cologne, Essen, München, Rostock
Életkor
18 év to 100 év
People
162 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06562192
1. fázisTaking people
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Where
Berlin
Életkor
18 év and over
People
714 worldwide
Run by
Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT05208762 · EU 2023-506604-18-00
1. fázisNot yet taking people in Németország
First-in-Women Study Evaluating the Safety of Lutetium-177 Radioligand Therapy in Metastatic Triple-Negative Breast Cancer
Where
Aachen, Duesseldorf
Életkor
18 év and over
People
18
Run by
Universitaetsklinikum Aachen AöR
See details and how to join2025-524027-49-00 · EU 2025-524027-49-00
1/2. fázisTaking people
Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer
Where
Erlangen, Heidelberg, Tuebingen
Életkor
18 év and over
People
28
Run by
NEC Bio B.V
See details and how to joinNCT06631092 · EU 2024-512520-11-00
2. fázisTaking people
Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer
Where
Berlin, Bielefeld, Bonn, Eschweiler, Essen, Frankfurt Am Main, Georgsmarienhuette, Goslar, Munich, Troisdorf, Tuebingen, Witten
Életkor
18 év to 64 év
People
140 worldwide
Run by
Queen Mary University of London
See details and how to joinNCT06954480 · EU 2024-519913-76-00
No phaseTaking people
Immunotherapy-related CRP Kinetics in Early and Metastatic Triple-negative Breast Cancer
Where
Tübingen
Életkor
18 év and over
People
225
Run by
University Hospital Tuebingen
See details and how to joinNCT05914961
No phaseNot yet taking people in Németország
Neutrophil Biomarker Test for Predicting Clinical Benefit From Immunotherapy Based on Flow Cytometry Analysis
Where
Heidelberg
Életkor
18 év and over
People
600 worldwide
Run by
OncoHost Ltd.
See details and how to joinNCT07246759